Drugs / GLA-SE adjuvant
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04927585 | Jul 2021 → Dec 2023 | HIV infectious disease | Worcester HIV Vaccine | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07675629 | Sep 2026 → Aug 2028 expected | — | Worcester HIV Vaccine | Not yet recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT03409276 Background | Mar 2018 → May 2020 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT03220724 Background | Aug 2017 → Mar 2023 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GLA-SE adjuvant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03220724 ↗ |
| Route | Intramuscular | “Participants in Part B will be randomly assigned to one of four groups. Participants in each group will receive IM injections at Months 0, 2, 4, 8. GLA-SE will be admixed with...” NCT03220724 ↗ |